Stifel analyst Rick Wise noted that he hosted an investor dinner with LivaNova management in conjunction with the firm's healthcare conference last week, after which he has increased confidence in LivaNova's ongoing turnaround and transformation. CEO Damien McDonald emphasized the company will enter 2020 on a more solid foundation and management seemed confident the portfolio can drive sustained mid-single digits growth, Wise tells investors. Separately, the heart valve business restructuring and Caisson-TMVR program exit should aid focus and improve execution, said Wise, who raised his price target on LivaNova shares to $90 from $80 and keeps a Buy rating on the stock.